Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical CoKKPCF 62 EV-to-EBIT is 39.69 as of Jul. 28, 2026, which is 533% above its 10-year median of 6.27. GuruFocus rates KKPCF with a GF Score™ of 62/100 and a GF Value™ of $25.52. The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, Kaken Pharmaceutical Co ranks worse than 83.36% on this metric.
Kaken Pharmaceutical Co (OTCPK:KKPCF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kaken Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was $689.3 Mil.
Kaken Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co EV-to-EBIT Related Terms
Kaken Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's EV-to-EBIT falls into.
Kaken Pharmaceutical Co's current Enterprise Value is $621.0 Mil.
Kaken Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (KKPCF) has a EV-to-EBIT of 39.69 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kaken Pharmaceutical Co and its competitors. This is 533% above median its historical median of 6.27. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #576 out of 691 companies in the Drug Manufacturers industry, placing it in the top 83.4%.
Is Kaken Pharmaceutical Co's EV-to-EBIT too high?
Kaken Pharmaceutical Co's current EV-to-EBIT of 39.69 is 533% above median its 10-year median of 6.27. The Drug Manufacturers industry median EV-to-EBIT is 15.42. Kaken Pharmaceutical Co's value of 39.69 is 157.4% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #576 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kaken Pharmaceutical Co has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #576 out of 691 companies for EV-to-EBIT. This places Kaken Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 15.42. Kaken Pharmaceutical Co's value of 39.69 is 157.4% above this benchmark. While the company's 10-year median is 6.27 vs. the industry median of 15.42, Kaken Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current EV-to-EBIT of 39.69 is 157.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current EV-to-EBIT is 39.69, which is 533% above median its own 10-year median of 6.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current EV-to-EBIT of 39.69. The stock's GF Value™ is $25.52, compared to a current price of $26.00 — trading 1.9% above its estimated fair value. The current EV-to-EBIT is 39.69, which is 533% above median its 10-year median of 6.27 and 157.4% above the Drug Manufacturers industry median of 15.42. Kaken Pharmaceutical Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current EV-to-EBIT is 39.69 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of $26.00 is trading 1.9% above its estimated GF Value™ of $25.52.
Key valuation signals for KKPCF:
EV-to-EBIT: 39.69 (533% above median its 10-year median of 6.27)
GF Value™: $25.52 vs. price of $26.00 (1.9% above fair value)
Industry Position: 157.4% above the Drug Manufacturers median (#576 of 691)
No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
62GF Score
Get the complete analysis for KKPCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KKPCF has been successfully added to your 
